Tower Research Capital LLC TRC decreased its position in Stevanato Group S.p.A. (NYSE:STVN – Free Report) by 48.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,189 shares of the company’s stock after selling 1,119 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Stevanato Group were worth $32,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the company. Raymond James & Associates lifted its holdings in Stevanato Group by 0.9% in the third quarter. Raymond James & Associates now owns 197,316 shares of the company’s stock worth $5,864,000 after acquiring an additional 1,806 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stevanato Group during the 3rd quarter valued at approximately $255,000. Calamos Wealth Management LLC bought a new position in Stevanato Group during the 3rd quarter worth $1,456,000. Conestoga Capital Advisors LLC increased its position in Stevanato Group by 19.7% in the third quarter. Conestoga Capital Advisors LLC now owns 4,534,088 shares of the company’s stock worth $134,753,000 after buying an additional 746,136 shares during the period. Finally, Fifth Third Bancorp lifted its stake in Stevanato Group by 70.1% in the third quarter. Fifth Third Bancorp now owns 2,473 shares of the company’s stock valued at $73,000 after buying an additional 1,019 shares during the last quarter.
Stevanato Group Price Performance
Shares of NYSE STVN traded down €0.36 ($0.39) during mid-day trading on Friday, reaching €26.45 ($28.44). 277,600 shares of the company traded hands, compared to its average volume of 336,883. The firm has a market cap of $7.82 billion, a PE ratio of 44.83, a price-to-earnings-growth ratio of 2.96 and a beta of 0.76. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.50 and a quick ratio of 1.06. Stevanato Group S.p.A. has a fifty-two week low of €23.00 ($24.73) and a fifty-two week high of €36.30 ($39.03). The stock has a fifty day simple moving average of €29.63 and a 200-day simple moving average of €29.20.
Wall Street Analysts Forecast Growth
STVN has been the topic of a number of analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $30.00 price objective on shares of Stevanato Group in a report on Monday, April 22nd. BNP Paribas started coverage on Stevanato Group in a report on Monday, April 22nd. They set an “outperform” rating on the stock. Finally, Stephens reissued an “overweight” rating and issued a $38.00 price objective on shares of Stevanato Group in a report on Monday, March 25th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of €33.63 ($36.16).
Get Our Latest Stock Analysis on STVN
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
See Also
- Five stocks we like better than Stevanato Group
- What Are Dividend Contenders? Investing in Dividend Contenders
- MarketBeat Week in Review – 4/29 – 5/3
- Upcoming IPO Stock Lockup Period, Explained
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Dividend Capture Strategy: What You Need to Know
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.